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Abstract
Background: Impaired balance is a major problem in patients with idiopathic Parkinson’s disease (PD) resulting in an
increased risk of falls and fall-related fractures. Most studies which analyzed the risk of femoral fractures in patients with
idiopathic PD were performed either in specialized centers or excluded very frail patients. The current study used a large
population-based dataset in order to analyze the risk of femoral fractures in patients with idiopathic PD.
Methods: Data from more than 880.000 individuals aged 65 years or older and insured between 2004 and 2009 at a large
German health insurance company were used for the analyses. Persons with idiopathic PD were identified by the dispensing
of Parkinson-specific medication and by hospital diagnoses, if available. People without PD served as the reference group.
Incident femoral fractures were obtained from hospital diagnoses. Analyses were stratified by gender and information on
severe functional impairment (care need) as provided by reimbursement claims.
Results: Compared with the reference group, persons with idiopathic PD had a more than doubled risk to sustain a femoral
fracture. The risk was higher in men (HR= 2.61; 95%-CI: 2.28–2.98) than in women (HR= 1.79; 95%-CI: 1.66–1.94). The
increased risk was only observed in people without severe functional impairment. The sensitivity analysis using a refined
definition of idiopathic PD patients yielded similar results.
Conclusion: The findings confirm the increased risk of femoral fractures in patients with idiopathic PD. The relative risk is
particularly high in male PD patients and in patients without severe functional impairment.
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Introduction
Parkinson’s disease (PD) is the second most common neurode-
generative disorder after Alzheimer’s disease [1]. Postural insta-
bility and impaired balance is one of the cardinal symptoms of PD
posing these patients at an increased risk of falling [2–7]. Fall-
related injuries represent the most frequent reason for hospital
admission in PD [8]. The occurrence of falls in patients with PD
has been shown to be associated with increasing age, severity of
symptoms, and use of dopaminergic drugs [3,4,7,9].
The increased risk of falling in combination with a low bone
mineral density is putting PD patients at high risk for osteoporotic
fractures [10]. In several studies, PD patients were found to have a
high rate of fractures [2,11–16]. Among these, femoral fractures
are the most common type of non-vertebral fractures [7,12–
14,16]. Femoral fractures are associated with high morbidity,
mortality, and costs in the general older population [17–19]. In
PD patients, femoral fractures are associated with a particularly
high risk of unfavorable outcomes such as admission to nursing
homes [20]. However, estimates of the magnitude of these
patients’ increased risk are mainly based on observational studies
with a limited number of PD patients and only a low number of
femoral fractures [13–16].
PD is characterized by loss of functional abilities as the disease
progresses [21–23]. However, the influence of functional limita-
tions on the excess risk for femoral fractures in PD patients has not
been explored so far. A large German population-based dataset
containing routine data allowed us to identify older individuals
with severe functional limitations in activities of daily living. The
aim of this study was (1) to estimate the risk of idiopathic PD
patients to sustain a femoral fracture and (2) to stratify this estimate
for the presence of severe functional impairment.
Materials and Methods
Data Source
The routine data collection systems of the largest health
insurance company in Bavaria, the Allgemeine Ortskrankenkasse Bayern
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(AOK Bavaria), was used to select data on gender, age, long term
care need, admission to hospital, admission and discharge
diagnosis as well as dispensed medication. Health insurance and
long term care insurance is statutory in Germany. The AOK
Bavaria covers nearly 50% of the population aged 65 years and
over in Bavaria, a federal state with 12.5 million inhabitants.
Data on Medication to Treat PD
Within the stored data of the AOK Bavaria, all prescriptions for
medication for the treatment of PD were identified (Tab. 1).
Substances were categorized according the Anatomical Thera-
peutic Chemical Classification System (ATC code) to substance
classes. In Germany, outside hospitals Parkinson medication is
available only at pharmacies with a written prescription by a
physician and is reimbursed by the person’s health insurance. For
reimbursement, a person’s insurance number along with type,
dose and amount of drug prescribed, as well as prescription date is
transferred to the health insurance. No information on the dosage
regime or diagnosis is transferred. Data on reimbursement held by
health insurances give complete information on all prescriptions
filled in.
Study Population
The dataset consisted of 932,197 people aged 65 years and over
who were member at AOK Bavaria between January 1st 2004 and
June 30th 2009. Data from the year 2004 (January 1st to December
31st) regarding admission or discharge diagnoses as well as PD
medications were used to identify patients with idiopathic PD.
Individuals dying in 2004 were not considered (N=44,333).
Identification of the study population and sub-groups is displayed
in figure 1.
Identification of Individuals with Idiopathic PD
Identification of patients with PD using routine data is not
straightforward. In our dataset we could use two types of
information to identify PD patients: (1) primary hospital admission
and discharge diagnoses of hospitalized patients, and (2) informa-
tion about antiparkinson medication dispensed by pharmacies
outside the hospital. Hospital admission and discharge diagnoses
covered only a small percentage of PD patients. Therefore, the
main information to identify patients with idiopathic PD was the
medication to treat PD.
We defined individuals as patients with an idiopathic PD if a)
antiparkinson medication was dispensed at least twice in 2004, or
once in 2004 and at least once in 2005 or b) idiopathic PD was the
primary hospital admission or discharge diagnosis in 2004 (ICD-
10: G20) and antiparkinson medication was dispensed at least once
in 2004.
Most patients with idiopathic PD are treated with antiparkinson
drugs and are covered by the chosen method. However, some
other disease entities are also treated by antiparkinson drugs like
atypical Parkinsonism, secondary Parkinsonism or restless legs
syndrome (RLS). Therefore, these individuals were excluded if
they could be identified by hospital admission or discharge
diagnoses (ICD-10) (G21/G22/G23/G25.81). The final dataset
comprised 323, 404 men and 560, 453 women.
This dataset still included patients with atypical Parkinsonism,
secondary Parkinsonism or RLS. Atypical Parkinsonism and
secondary Parkinsonism are very rare diseases. RLS, however,
has a higher prevalence and might account for a relevant
percentage of the dispensed antiparkinson medication. Medically
treated RLS is usually treated by monotherapy with dopaminergic
drugs. Therefore, we applied two different models to perform a
sensitivity analysis. Model I (‘possible’ idiopathic PD patients) used
data of all patients with antiparkinson medication (see above).
Most patients with a RLS are still included in this model. Model II
(‘probable’ idiopathic PD patients) excluded all individuals
(n = 11,078) from model I who received levodopa only or
dopamine agonists only (change of substance within and between
substance class possible). In this model most patients with a RLS
but also patients with an idiopathic PD treated by monotherapy
with dopaminerigic drugs are excluded. Therefore, model II may
over-represent patients with an advanced idiopathic PD.
Please note that these terms are not synonymous with the terms
for clinical definition of PD [24] and are therefore put in brackets
throughout this article.
Reference group: The reference group comprised of individuals
without intake of antiparkinson medication and no hospital
admission or discharge diagnosis of atypical Parkinsonism,
secondary Parkinsonism or RLS in 2004.
Definition of Severe Functional Impairment
The need for long-term nursing care was used as a marker for
severe functional impairment and was assessed at the beginning of
the observation period (January 1st 2005). In Germany, most
persons with a minimum of six months of need for nursing care are
eligible to receive reimbursement for long-term care by the long-
term care insurance. The long-term care insurance was introduced
in the German social insurance system in 1995. All employed
citizens are members by law [25]. Experts confirm a person’s
eligibility to receive long-term care benefit. Long-term care
Table 1. Medication considered as treatment for PD.
ATC codes
Levodopa N04BA01/N04BA02
Dopamine agonists
Apomorphine N04BC07
Bromocriptine N04BC01
Cabergoline N04BC06
Lisurid N04BC10
Pergolide N04BC02
Pramipexole N04BC05
Ropinirole N04BC04
Rotigotine N04BC09
Anticholinergics
Biperiden N04AA02
Bornaprine N04AA11
Methixine N04AA03
Procyclidine N04AA04
Trihexphenidyl N04AA01
Budipine N04BX03
COMT inhibitor
Entacapone N04BX02
Tolcapone N04BX01
MAO B inhibitors
Rasagiline N04BD02
Selegiline N04BD01
Amantadine N04BB01
Stalevo N04BA03
doi:10.1371/journal.pone.0097073.t001
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benefits are granted for professional, family, and/or informal help.
In order to claim long-term care benefits, people must have a daily
minimum of 90 minutes of assistance with basic activities of daily
living (ADL) such as washing, eating, or dressing, and instrumental
activities of daily living (IADL) such as cleaning or shopping. This
information thus defines relatively well functional impairment,
independent of underlying diseases.
Identification of Femoral Fractures
Hospital discharge diagnoses were used to identify femoral
fractures (ICD-10: S72). The observation period started on
January 1st 2005 and ended on June 30th 2009. Hospital
admissions coding a femoral fracture that occurred within less
than 30 days to a previous fracture were excluded in order to avoid
double coding.
Figure 1. Flow chart of study population and model definitions. Identification was based on characteristics in 2004 as provided by the health
insurance company (AOK: Allgemeine Ortskrankenkasse Bavaria) PD: Parkinson’s disease; N: number of participants.
doi:10.1371/journal.pone.0097073.g001
Table 2. Characteristics of the study population.
Reference group PD medication
Model I (possible PD) Model II (probable PD)
Total [N (%)] 860,388 (97.3%) 23,469 (2.7%) 12,391 (1.4%)
Age (y) [Median, IQR] 74.4 (69.7–80.2) 77.9 (72.7–83.1) 76.9 (72.0–82.0)
Women (%) 63.3 66.2 62.7
Follow-up (y) [Median, IQR] 4.50 (4.50–4.50) 4.50 (2.40–4.50) 4.50 (2.47–4.50)
Number of femoral fractures (N) 33,228 1,633 919
Persons with 1 femoral fracture (N) 28,939 1,407 785
Persons with $2 femoral fractures (N) 2,104 110 66
Persons without care need [N (%)] 750,806 (87.3%) 12,263 (52.3%) 6,153 (49.7%)
Age (y) [Median, IQR] 73.4 (69.3–78.6) 75.1 (70.7–79.9) 74.5 (70.2–79.0)
Women (%) 61.6 64.9 60.3
Persons with care need [N (%)] 109,582 (12.7%) 11,206 (47.7%) 6,238 (50.3%)
Age (y) [Median, IQR] 83.5 (77.9–89.4) 81.2 (76.0–85.3) 79.6 (74.6–84.0)
Women (%) 75.4 67.7 65.0
PD: Parkinson’s disease; N: Number; y: Years, IQR: Inter quartile range.
Characteristics of study population at start of the observation period (January 1st 2005) and number of fractures between January 1st 2005 and June 30th 2009.
doi:10.1371/journal.pone.0097073.t002
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Statistics
The accumulation of the individual person-years of individuals
with PD and without (reference group) started at beginning of
observation period (January 1st 2005) and ended with censoring
due to death or at the end of the observation period. Fracture rates
and 95% confidence intervals were estimated per 1000 person-
years and adjusted for age using negative binomial regression
models. To quantify the relative risk for the first femoral fracture
during observation time in people with ‘possible’ or ‘probable’
idiopathic PD compared to people without PD hazard ratios with
95% confidence intervals were calculated. In the applied
proportional hazards models age of participants was used as
‘survival time’-variable to adjust for age and to account for the fact
that the participants were of different ages at study begin. All
models were stratified for sex and considered severe functional
impairment by stratification. All statistical calculations were
carried out using SAS version 9.3 (SAS Institute Inc., Cary, NC,
USA).
Ethics
The study was approved by the Ethical committee of Ulm
University.
Results
A total of 883,857 individuals aged 65 years and older were
included in our study population. The median follow-up was 4.5
years. As ‘possible’ PD patients (model I) 23,469 individuals (2.7%)
were identified and 12,391 (1.4%) as ‘probable’ idiopathic PD
patients (model II). Table 2 shows baseline characteristics of the
reference group as well as of individuals with ‘possible’ PD (model
I) and ‘probable’ PD (model II). In both models, PD-patients were
older than the reference group (77.9, 76.9 years vs. 74.4 years in
individuals with ‘possible’ PD, ‘probable’ PD, and in individuals of
the reference group, respectively). A higher proportion of these
individuals had severe functional impairment (47.7, 50.3 and
12.7% of the population with ‘possible’ PD, ‘probable’ PD, and of
individuals of the reference group, respectively). However, the
median age of individuals with severe functional impairment was
younger in both models compared to the reference group (81.2/
79.6 years vs. 83.5 years, as for individuals with ‘possible’ PD,
‘probable’ PD, and for individuals of the reference group,
respectively).
As displayed in Table 3, the most commonly prescribed
medication of individuals with ‘possible’ PD was levodopa either
Table 3. Frequency of prescribed Parkinson medication of
persons identified with ‘possible’ Parkinson’s diseases (PD).
Number (%)*
Monotherapy
Levodopa{ 10,880 (46.4%)
Dopamine agonists{ 425 (1.8%)
Others1 4,249 (18.1%)
Combinations
Levodopa + dopamine agonists 2,074 (8.8%)
Levodopa + others1 2,951 (12.6%)
Dopamine agonists + others1 136 (0.6%)
Other combinations 2,754 (11.7%)
*percentage refers to all persons included in model I (‘possible’ PD).
{model II (‘probable’ PD) excludes persons treated with levodopa only or
dopamine agonists only.
1Others: amantadine, MAO B inhibitors, anticholinergic agents, budipine.
doi:10.1371/journal.pone.0097073.t003
Figure 2. Age-adjusted risk of a first femoral fracture during a median observation period of 4.5 years. Individuals with ‘possible’
(N = 23,469) or ‘probable’ (N = 12,391) idiopathic Parkinson’s disease (PD, for definition see text) were compared to 860,388 people without PD,
stratified by gender and care need.
doi:10.1371/journal.pone.0097073.g002
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alone or in combination (79.0%). Only 1.8% of individuals
received dopamine agonists alone and 9.4% in combination.
Estimates of fracture rates were based on 34,861 femoral
fractures overall. Table 4 shows age adjusted fracture rates
stratified by severe functional impairment and gender. Rates for
femoral fractures are ranging from 3/1000 to 33/1000 person-
years. In all strata and models, women had a higher fracture rate
than men. The relative difference was less pronounced in
individuals with ‘possible’ or ‘probable’ idiopathic PD with severe
functional impairment. Figure 2 illustrates hazard ratios (HR)
using the same strata. Narrowing the criteria from model I to
model II increased the HR from 2.27 to 2.61 in men, and from
1.51 to 1.79 in women. The HR was higher in men than in women
in both models (HR 2.27 vs. 1.51/2.61 vs. 1.79 in model I/II,
respectively). In individuals without severe functional impairment,
the relative fracture risk was higher than in those with functional
impairment. In fact, women with ‘probable’ idiopathic PD and
severe functional impairment did not have an increased risk to
sustain a femoral fracture compared to women of the reference
group. Men with ‘probable’ idiopathic PD and functional
impairment had a low risk increase for femoral fractures of
24%. Both models showed similar results (Fig. 2).
Discussion
In this large-scale analysis of population-based data of a health
insurance company we compared femoral fracture rates in older
individuals with ‘possible’ or ‘probable’ PD to a reference group
without PD. The rates of femoral fractures found in our analysis
are comparable to rates of femoral fractures previously reported
[26–28].Our data demonstrate that individuals aged 65 years or
older with medically treated idiopathic PD have a more than
doubled (men) or almost doubled (women) risk to sustain a femoral
fracture compared to the reference group. To test the robustness of
our results and the susceptibility to the inclusion and exclusion
criteria, two models with refined definitions were used. ‘Possible’
PD (model I) showed lower hazard ratios compared to ‘probable’
PD (model II). Both models showed a similar picture with a higher
hazard ratio in those PD patients without severe functional
impairment compared to PD patients with severe functional
impairment and higher hazard ratio in men compared to women.
In PD patients, one out of four falls results in an injury [6]. Falls
and fractures represent the leading diagnosis for admission to
hospital in PD patients [8]. Our finding of an increased risk for
femoral fractures in PD is in line with previous studies that
demonstrated an association of PD with an increased risk of falling
and a decreased bone mineral density [10]. A meta-analysis
pooling data from six prospective studies found 46% of PD
patients to fall over a three month period [6]. In addition to known
risk factors such as age, female gender and previous falls, various
disease-specific risk factors are under discussion such as pathologic
gait characteristics [5,29,30], balance problems [5,29], impaired
cognition [29,31], and the use of dopaminergic drugs [5,9].
However, the excess risk we found is lower than the values
reported previously ranging from a 2.2- to a 4.6-fold risk [12,14–
16,32]. Our study is based on an unselected population-based
sample of individuals including all stages of PD and including
community-dwelling older individuals as well as nursing home
residents (in both, PD patients and the reference group). This
approach is in clear contrast to a number of studies recruiting from
either specialist clinics or cohort studies that excluded the frailest
of these patients. Such an example of a non-representative sample
would be the Osteoporotic Fractures in Men study (MrOS) that
explicitly excluded men unable to walk without personal assistance
T
a
b
le
4
.
A
g
e
-a
d
ju
st
e
d
fe
m
o
ra
l
fr
ac
tu
re
ra
te
s
(p
e
r
1
,0
0
0
p
e
rs
o
n
-y
e
ar
s)
o
f
p
e
rs
o
n
s
ag
e
d
6
5
an
d
o
ld
e
r.
T
o
ta
l
W
it
h
o
u
t
ca
re
n
e
e
d
W
it
h
ca
re
n
e
e
d
N
o
.
o
f
fe
m
o
ra
l
fr
a
ct
u
re
s
P
e
rs
o
n
-y
e
a
rs
F
e
m
o
ra
l
fr
a
ct
u
re
s/
1
0
0
0
p
e
rs
o
n
-y
e
a
rs
(9
5
%
C
I{
)
N
o
.
o
f
fe
m
o
ra
l
fr
a
ct
u
re
s
P
e
rs
o
n
-y
e
a
rs
F
e
m
o
ra
l
fr
a
ct
u
re
s/
1
0
0
0
p
e
rs
o
n
-y
e
a
rs
(9
5
%
C
I{
)
N
o
.
o
f
fe
m
o
ra
l
fr
a
ct
u
re
s
P
e
rs
o
n
-y
e
a
rs
F
e
m
o
ra
l
fr
a
ct
u
re
s/
1
0
0
0
p
e
rs
o
n
-y
e
a
rs
(9
5
%
C
I{
)
R
e
fe
re
n
ce
g
ro
u
p
M
e
n
6
,4
0
0
1
,2
6
4
,8
4
0
.9
1
4
.1
5
(4
.0
3
–
4
.2
8
)
4
,8
7
1
1
,1
9
3
,8
8
7
.2
5
3
.3
5
(3
.2
3
–
3
.4
6
)
1
,5
2
9
7
0
,9
5
3
.6
5
2
1
.5
9
(2
0
.5
9
–
2
2
.7
4
)
W
o
m
e
n
2
6
,8
2
8
2
,2
0
2
,9
8
4
.7
2
9
.9
2
(9
.7
7
–
1
0
.0
6
)
1
9
,1
7
4
1
,9
6
7
,7
3
5
.2
8
7
.5
3
(7
.3
9
–
7
.6
6
)
7
,6
5
4
2
3
5
,2
4
9
.4
4
3
2
.8
8
(3
2
.1
4
–
3
3
.6
4
)
P
D
tr
e
at
m
e
n
t
M
o
d
e
l
I
(p
o
ss
ib
le
P
D
)
M
e
n
3
7
8
2
6
,5
0
1
.7
9
1
3
.7
4
(1
2
.3
2
–
1
5
.3
3
)
1
5
5
1
6
,9
4
9
.3
1
8
.0
7
(6
.7
3
–
9
.6
8
)
2
2
3
9
,5
5
2
.4
8
2
3
.6
4
(2
0
.6
7
–
2
7
.0
4
)
W
o
m
e
n
1
,2
5
5
5
5
,0
8
4
.9
7
2
2
.4
7
(2
1
.1
7
–
2
3
.8
5
)
5
9
3
3
3
,0
0
2
.0
0
1
5
.7
8
(1
4
.3
4
–
1
7
.3
8
)
6
6
2
2
2
,0
8
2
.9
7
3
0
.4
0
(2
8
.1
6
–
3
2
.8
3
)
M
o
d
e
l
II
(p
ro
b
ab
le
P
D
)
M
e
n
2
3
4
1
5
,7
0
1
.4
4
1
4
.4
7
(1
2
.6
0
–
1
6
.6
2
)
9
2
9
,6
7
2
.5
0
8
.8
0
(7
.0
0
–
1
1
.0
7
)
1
4
2
6
,0
2
8
.9
5
2
3
.7
2
(2
0
.0
1
–
2
8
.1
1
)
W
o
m
e
n
6
8
5
2
7
,5
8
8
.0
1
2
4
.7
2
(2
2
.8
2
–
2
6
.7
8
)
3
2
7
1
5
,3
2
8
.2
3
1
9
.1
0
(1
6
.8
1
–
2
1
.7
1
)
3
5
8
1
2
,2
5
9
.7
8
2
9
.5
9
(2
6
.6
5
–
3
2
.8
4
)
P
D
:
P
ar
ki
n
so
n
’s
d
is
e
as
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
9
7
0
7
3
.t
0
0
4
Femoral Fractures in Parkinson’s Disease
PLOS ONE | www.plosone.org 5 May 2014 | Volume 9 | Issue 5 | e97073
[11,33]. A similar approach was chosen for the recruitment of
another cohort [14]. Considering the fact that the risk of falling
increases with the disease stages [4,6], the advantage of a
population-based approach is apparent.
This study introduces an additional approach which may be
useful for a better interpretation of the observed risk. We were able
to stratify the cohorts according to the need for long-term nursing
care as a functional parameter. About every other PD patient in
our dataset required long-term nursing care. Stratifying our
analyses by this indicator for severe functional impairment, we
retrieved a more complex picture. PD patients without severe
functional impairment had a more than two fold risk to sustain a
femoral fracture, compared to the reference group. In contrast,
PD patients with severe functional impairment did not (women) or
only slightly (men) differ from the reference group with severe
functional impairment. Although we could confirm that PD is a
risk factor for femoral fractures, the above data indicate that not
the diagnosis per se, but functional impairment as a consequence
of PD contributes relevantly to the risk of femoral fractures. Severe
functional impairment expressed as care need has been shown to
be a risk factor for factures [34,35] The analysis of PD patients
versus a reference group presented in this study implies that not
the underlying disease is attributable for this risk but the need for
help with ADLs.
Our approach has several limitations that need to be considered
when interpreting the findings. The dataset used does not allow
diagnosis of PD with very high security. However, by introducing
a ‘possible’ and ‘probable’ PD model (which showed comparable
results) and by choosing definitions that make the inclusion of
severe atypical Parkinsonism (with an even higher risk of falls) in
the PD cohort very probable, we argue that our approach might
rather over- than under-estimate the fracture risk in the PD group.
Moreover, data from the Rotterdam study indicates that our
model approach indeed has a high accuracy to detect the persons
of interest: They found 78% of users of Parkinson medication to
have clinically confirmed idiopathic PD; intake of more than one
substance class yield 100% specificity [36]. The most prevalent
other condition treated with dopaminergic drugs is the restless legs
syndrome (RLS) [37]. Further arguments for the usefulness of the
PD models introduced here are provided by results of epidemi-
ological studies investigating treatment behavior of the most
relevant ‘‘confounding’’ disease, i.e. RLS. These studies found
that, contrary to what is recommended in the guidelines, only a
minority of patients are treated with dopaminergic drugs [38–40].
Another shortcoming of our data is the lack of information on
dosage. Data from Denmark demonstrated a dose-dependent
association between fracture risk and Parkinson’s medication [15].
Reimbursement data in the dataset used in our study did not allow
reliable calculation of dosage in the absence of regimes.
We identified persons as ‘possible’ PD (model I) and ‘probable’
PD based on medication records in 2004. We could not trace back
the duration of dispensing for a longer time period. Hence, this
study does not allow any conclusions with respect to the duration
of PD.
Our data were derived only from one health insurance
company and may not be representative for the whole German
population. However, the AOK is the by far largest statutory
health care insurance and is open to all people. In Bavaria, the
AOK covers almost 50% of the population aged 65 years and
older, thus we argue that this is indeed a representative sample.
Conclusions
Our findings confirm the increased risk of femoral fractures in
PD patients. However, according to our large population-based
dataset it is lower than previously reported. Interestingly,
diagnosis-specific differences in fracture risk was observable only
in PD patients without severe functional impairment, whereas PD
patients and the reference group with severe functional impairment
did not show relevant differences in fracture risk. This may have
relevant implications for disease-specific falls prevention programs
in PD patients. Such programs may be most effective in early
rather than in advanced stages of the disease.
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